

Patent Selections:

The patents annotated in this section have been selected from various patent collections. They are recent patents categorized by therapeutic area/agent/target and therapeutic agents related to anti-cancer drug discovery and are relevant to the articles published in this journal issue.

THERMOSENSITIVE CYCLOTRIPHOSPHAZENE-PLATINUM COMPLEX

1. Sohn, Y.S., Song, S.-C., Lee, Sang B.L. Thermo-sensitive cyclotriphosphazene-platinum complex conjugate, its preparation method and anticancer agent containing the same *EP1311519A4* (2005).
2. Youn S.S., Soo-Chang S., Sang B.L. Thermosensitive cyclotriphosphazene-platinum complex conjugate, its preparation method and anticancer agent containing the same *AU0781233B2* (2005).

PLATINUM COMPLEX AND AS ANTICANCER AGENTS

1. Lewis, J., Hoos, A., Gale, R.P. Combination chemotherapy comprising a liposomal platinum Complex *WO04103344A1* (2004).

MATRIX METALLOPROTEINASE INHIBITOR

1. McKearn, J.P., Gordon, G., Cunningham, J.J., Gately, S.T., Koki, A.T., Masferrer, J.L. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia *US6858598* (2005).
2. Warner-Lambert Company. Pyrimidine matrix metalloproteinase inhibitors *US6936616* (2005).
3. Chen, J.M., Mobilio, D., Moy, F.J., Parris, K.D., Powers, R., Bao X.Z. Methods for designing agents that interact with MMP-13 *US6934639* (2005).
4. Barvian, N.C., Connor, D.T., O'Brien, P.M., Ortwine, D.F., Patt, W.C., Shuler, K.R., Wilson, M.W. Pyridine matrix metalloproteinase inhibitors *US6881743* (2005).
5. McKearn, J.P., Gordon, G., Cunningham, J.J., Gately, Stephen T., Koki, A.T., Masferrer, J.L. Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent *US20050058725A1* (2005).
6. McKearn, J.P., Gordon, G., Cunningham, J.J., Gately, Stephen T., Koki, A.T., Masferrer, J.L. Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent *US6916800* (2005).
7. Schudok, M., Matter, H., Hofmeister, A. Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors *WO05073236A2* (2005).
8. Schubert, G. Process for preparing cyclic N-substituted alpha-imino carboxylic acids *US20050131231A1* (2005).
9. Sorenson, R.J. Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors *US6924276* (2005).

10. Wantanabe, F., Suzuki, H., Ohtani, M. Isonated amino acid derivatives and metalloproteinase inhibitors containing the same *US6919375* (2005).
11. Burrows, J., N., Tucker, H., Waterson, D., Finlay, M.R.V. Onylpiperidine derivatives containing a aryl or heteroaryl group for use as matrix metalloproteinase inhibitors *EP1539159A1* (2005).
12. Gaudilliere, B., Jacobelli, H., Kostlan, C., Li, J.J., Yue, W.- S. Oxo-azabicyclic compounds *US6894057* (2005).

GELATINASES AND MATRIX METALLOPROTEINASE INHIBITORS

1. Quirk, S., Malik, S. Anti-aging and wound healing compounds *US6906036* (2005).
2. Stallings, W.C., Shieh, H.S., Howard, S.C., DeCrescenzo, G.A., McDonald, J.J. Method of changing conformation of a matrix metalloproteinase *US6869951* (2005).
3. Copeland, R.A., Albright, C.F., Combs, A.P., Dowling, R.L., Graciani, N.R., Han, W., Higley, C.A., Huang, P.S., Yue, E.W., DiMeo, S.V. Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use *US6844318* (2005).
4. Zhu, Z., Mazzola, R., Guo, Z., Lavey, B.J., Sinning, L., Kozlowski, J., McKittrick, B., Shih, N.-Y., Compounds for the treatment of inflammatory disorders *US6838466* (2005).

NUTRACEUTICALS AND CANCER

1. Khanuja, S.P.S., Kumar, S., Shasany, A.K., Arya, J.S., Darokar, M.P., Singh, M., Sinha, P., Awasthi, S., Gupta, S.C., Gupta, V.K., Gupta, M.M., Verma, R.K., Agarwal, S., Mansinghka, S.B., Dawle, S.H. Use of bioactive fraction from cow urine distillate ('go-mutra') as a bio-enhancer of anti-infective, anti-cancer agents and nutrients *US6896907* (2005).

PROTEASE INHIBITORS AND CANCER

1. Hembrough, T., Pribluda, V.P., Papathanassiou, A.E., Green, S.J. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments *US6946439* (2005).
2. Aschenbrenner, A., Fuchs, K.A., Dormeyer, M., Garcia, G., Kramer, B., Kraus, J., Krauss, R., Leban, J., Pegoraro, S., Saeb, W., Wolf, K. Compounds for the treatment of protozoal diseases *US6949567* (2005).
3. Smith, T.H. Pro-inflammatory fibrinopeptide *US6908899* (2005).
4. Allen, D.A., Hataye, J.M., Hruzewicz, W.N., Kolesnikov, A., Mackman, R.L., Rai, R., Jeffrey, S.R.,

- Verner, E.J., Young, W.B., Shrader, W.D. (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors *US6867200 (2005)*.
5. Falchuk, K.H. Compounds and methods for regulating cell differentiation *US6902881 (2005)*.
 6. Johnson, T.O. Jr., Hua, Y., Luu, H.T., Dragovich, P.S. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis *US6872745 (2005)*.
 7. Tsukamoto, T., Majer, P., Hin, B., Xu, W., Liu, Q., Stoermer, D. Hydroxamic acids and acyl hydroxamines as naaladase inhibitors *US6884907 (2005)*.
 8. Mundy, G.R., Garrett, I.R., Rossini, J.G. Inhibitors of proteasomal activity for stimulating hair growth *US6884769 (2005)*.
 9. Bandman, O., Hillman, J.L., Yue, H., Guegler, K.J., Corley, N.C., Tang, Y.T., Shah, P. Human protease molecules *US6855811 (2005)*.
 10. Dupont, E. Anti-tumor therapies comprising a combination of a cartilage extract and an anti-neoplastic agent providing high efficacy and low toxic side effects *US6855338 (2005)*.
 11. Shapiro, L. Inhibitors of serine protease activity, methods and compositions for treatment of viral infections *US6849605 (2005)*.
 12. Niestroj, A., Heiser, U., Demuth, H.-H. Inhibitors of dipeptidyl peptidase I *US6844316 (2005)*.
 13. Tabibi, S.E., Ezennia, E.I., Vishnuvajjala, B.R., Gupta, S. Water-insoluble drug delivery system *US6838090 (2005)*.
 9. Gleave, M., Rennie, P.S., Miyake, H., Nelson, C., Monia, B.P. TRPM-2 antisense therapy using an oligonucleotide having 2-O-(2-methoxy)ethyl modifications *US6900187 (2005)*.
 10. Bennett, C.F., Swayze, E.E., Ackermann, E.J., Cowser, L.M. Antisense modulation of survivin expression *US6838283 (2005)*.
 11. Keana, J.F.W., Cai, S.X., Guastella, J., Yang, W., Drewe, J.A., Weber, E. Dipeptide apoptosis inhibitors and the use thereof *US6949516 (2005)*.
 12. Lee, G.M., Kim, N.S. Inhibition of apoptosis by the expression of antisense RNA of caspase-3 *US6943022 (2005)*.
 13. Henry, M.O., Lynn, W.S. Modulation of cell fates and activities by diketo phthalazines *US6953799 (2005)*.
 14. Reed, J.C., Godzik, A., Chu, Z.-L., Pawlowski, K., Fiorentino, L., Ariza, M.E., Stehlik, C. Nucleic acid molecule encoding a PANG6 polypeptide *US6953691 (2005)*.
 15. Huang, D., Qi, D.F. Aglycon dammarane sapogenins, their use as anti-cancer agents, and a process for producing same *US6949523 (2005)*.
 16. Bertin, J. Molecules of the CARD-related protein family and uses thereof *US6953657 and US6942984 (2005)*.
 17. Barta, N.S., Bigge, C.F. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives *US6949575 (2005)*.
 18. Rustum, Y.M., Cao, S., Durrani, F. Method of reducing toxicity of anticancer agents *US6939893 (2005)*.
 19. Levine, Z., Bernstein, J. Variants of protein kinases *US6936450 (2005)*.
 20. Belmont, J.W., Fletcher, F.A., Chen, A.J., Jurecic, R., Tan, T.-H., Zhou, G. Phosphatases which activate map kinase pathways *US6900043 (2005)*.
 21. Wang, L., Liu, X., Chen, R. Derivatives of isoindigo, indigo and indirubin and methods of treating cancer *US6933315 (2005)*.
 22. Pasternack, G.R., Kochevar, G.J., Brody, J.R., Kadkol, S.S. Gene family with transformation modulating activity *US6930175 (2005)*.
 23. Yamamoto, H., Tsujikawa, K., Uchino, Y. Antibodies specific for intracellular domain of protein tyrosine phosphatase *US6933135 (2005)*.
 24. Nardella, F.A. Methods and compositions for the treatment of chronic lymphocytic leukemia *US6921772 (2005)*.
 25. Russell, S.J., Peng, K.-W. Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family *US6896881 (2005)*.
 26. Leng, J. Protease specific cleavable luciferases and methods of use thereof *US6890745 (2005)*.
 27. Tanzi, R.E., Kim, T.-W. Purified 20 kDa presenilin 2 C-terminal fragment and methods of screening for

INHIBITOR OF APOPTOSIS PROTEINS (IAPS)

1. Korneluk, R.G., Tamai, K., Liston, P., MacKenzie, A.E. XAF genes and polypeptides: methods and reagents for modulating apoptosis *US6946544 (2005)*.
2. Altieri, D.C. Survivin, a protein that inhibits cellular apoptosis and its modulation *US6943150 (2005)*.
3. Reed, J.C., Houghten, R.A., Nefzi, A., Ostresh, J.M., Pinilla, C., Welsh, K. Methods and compositions for derepression of IAP-inhibited caspase *US6911426 (2005)*.
4. Rothe, M., Goeddel, D.V. Inhibitors of apoptosis *US6855815 (2005)*.
5. Carroll, J.M., Pober, J.S. Use of interleukin-11 to prevent immune-mediated cytotoxicity *US6953777 (2005)*.
6. Pressman, N.J., Hirsch, A., Hirsch, K.S. Cell-based detection and differentiation of lung cancer *US6939670 (2005)*.
7. Altieri, D.C., O'Connor, D.S. Enhancement of taxane-based chemotherapy by a CDK1 antagonist *US6949558 (2005)*.
8. Shuber, A.P. Methods for disease detection *US6919174 (2005)*.

- compounds that inhibit proteolysis of presenilin 2 *US6887983 (2005)*.
28. Meyer-Almes, F.-J. Chemosensitivity determination using phosphatidylserine *US6949350 (2005)*.
 29. Adams, M.A., Graham, C.H., Heaton, J.P.W., Postovit, L.- M. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype *US6946484 (2005)*.
 30. Eastman, A.R., Krieser, R.J. Deoxyribonuclease II proteins and CDNAs *US6943014 (2005)*.
 31. Monteiro, M.J., Stabler, S. Method of controlling the binding of calmyrin to presenilin *US6930169 (2005)*.
 32. Huang, D., Qi, D.F. Dammarane sapogenins, their use as anti-cancer agents, and a process for producing same *US6888014 (2005)*.
 33. Feder, J.N., Ramanathan, C.S., Mintier, G.A. Polynucleotides encoding novel human leucine- rich repeat containing protein expressed predominately in bone marrow, HLRRBM1 *US6949363 (2005)*.
 34. Cai, S.X., Zhang, H., Kemnitzer, W.E., Jiang, S., Drewe, J., Storer, R. Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof *US6900325 (2005)*.
 35. Bertin, J. Molecules of the card-related protein family and uses thereof *US6936690 (2005)*.
 36. Komoriya, A., Packard, B.S. Compositions for the detection of enzyme activity in biological samples and methods of use thereof *US6936687 (2005)*.
 37. Vertino, P.M. TMS1 compositions and methods of use *US6911306 (2005)*.
 38. Baltimore, D., Yang, X., Chang, H.Y. Chimeric procaspases and methods of using same *US6916917 (2005)*.
 39. Drewe, J.A., Cai, S.X., Wang, Y. Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof *US6906203 (2005)*.
 40. Thatcher, Gr.R.J., Bennett, B.M., Reynolds, J.N., Boegman, R.J., Jhamandas, K. Nitrate esters and their use for neurological conditions *US6916835 (2005)*.
 41. Drewe, J.A., Cai, S.X., Shelton, E.J., Litvak, J., Sperandio, D., Spencer, J.R., Sendzik, M. Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof *US6861419 (2005)*.
 42. Cai, S.X., Xu, L., Storer, R., Attardo, G. 7, 8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof *US6858607 (2005)*.
 43. Rosen, A., Casciola-Rosen, L., Nicholson, D.W., Andrade, F.A., Roy, S., Thornberry, N.A. Auto-antigenic fragments, methods and assays *US6855515 (2005)*.
 44. Choong, I., Burdett, M., DeLano, W., Erlanson, D., Lee, D., Lew, W. Small molecule inhibitors of caspases *US6878743 (2005)*.
 45. Bertin, J. Card related protein and uses thereof *US6869775 (2005)*.
 46. Taylor, C., Wang, T.-W., Petrov, L., Carlson, J.C., Narayansingh, R., Thompson, J.E. DNA encoding apoptosis-induced eucaryotic initiation factor-5A and deoxyhypusine synthase and a method for controlling apoptosis in animals and humans *US6867237 (2005)*.
 47. Warrell, R.P.Jr., Pandolfi, P.P., Gabrilove, J.L. Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol *US6884439 (2005)*.
 48. Guo, K., Pagnoni, M.F., Clark, K.L., Ivashchenko, Y.D. AKT nucleic acids, polypeptides, and uses thereof *US6881555 (2005)*.
 49. Knobelsdorf, J., Hays, S., Stankovic, C.J., Para, K.S., Connolly, M.K., Galatsis, P., Harter, W., Shahripour, A.B., Plummer, M.S., Lunney, B., Janssen, B., Fell, J.B. Arylsulfonamide ethers, and methods of use thereof *US6875765 (2005)*.
 50. Giuliano, K., Kapur, R. System for cell-based screening *US6875578 (2005)*.
 51. Ellison, R.M., Mermelstein, F.H. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds *US6875451 (2005)*.
 52. Cravatt, B.F., Sorensen, E., Patricelli, M.P., Lovato, M., Adam, G. Proteomic analysis *US6872574 (2005)*.
 53. Ni, J., Gentz, R.L., Yu, G.-L., Rosen, C.A. Death domain containing receptor 5 antibodies *US6872568 (2005)*.
 54. Warrell, R.P. Jr., Pandolfi, P.P., Gabrilove, J.L. Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol *US6861076* and *US6855339 (2005)*.
 55. Payan, D. Toso as a target for drug screening *US6855495 (2005)*.
 56. Yamamoto, H., Tsujikawa, K., Uchino, Y., Konishi, N. Antibody against LAR phosphatase subunit *US6846912 (2005)*.
- ### HEMATOLOGICAL MALIGNANCIES
1. Cech, T.R., Lingner, J., Nakamura, T., Chapman, K.B., Morin, G.B., Harley, C.B., Andrews, W.H. Genes for human telomerase reverse transcriptase and telomerase variants *US6927285 (2005)*.
 2. Rybak, M.E., Rose, E.H. Melanoma therapy *US6923966 (2005)*.
 3. Hanna, N. Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma *US6896885 (2005)*.

ACUTE MYELOID LEUKEMIA

1. Liu, J.M., Wang, J. Cloning of the human nuclear receptor co-repressor gene *US6949624 (2005)*.
2. Banerjee, A.K., Giri, V.S., Mukherjee, R., Kapoor, K.K., Desiraju, G., Jaggi, M., Singh, A.T., Dutta, S.K., Sairam, K.V.V.M. Hydroanthracene based compounds as anticancer agents *US6949557 (2005)*.
3. Stauss, H.J. Immunotherapy using cytotoxic T lymphocytes (CTL) *US6805861 (2005)*.
4. Mazess, R.B., Bishop, C.W. Targeted therapeutic delivery of vitamin D compounds *US6929797 (2005)*.
5. Green, L.L., Bar-Eli, M. Antibodies against the MUC18 antigen *US6924360 (2005)*.
6. Call, K.M., Glaser, T.M., Ito, C.Y., Buckler, A.J., Pelletier, J.M., Haber, D.A., Rose, E.A., Housman, D.E., Bruening, W., Darveau A. Localization and characterization of the Wilms' tumor gene *US6943011 (2005)*.
7. Andreeff, M., Estey, Elihu H. Method of cancer treatment *US6929802 (2005)*.
8. Zhang, W.-W., Roth, J.A. Recombinant p53 adenovirus methods and compositions *US6905873 (2005)*.
9. Zingaro, R.A., Freireich, E.J., Duzkale, H., Kantarjian, H., Verstovsek, S., Sotelo-Lerma, M. S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer *US6911471 (2005)*.
10. Nehme, A., Beard, R.L., Chandraratna, R.A. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolanyl group in combination with other anti-tumor agents *US6903121 (2005)*.
11. Eugen-Olsen, J. Method and tool for prognosticating HIV infection in a subject by measuring soluble urokinase plasminogen activator receptor, degradation products thereof, and urokinase plasminogen activator receptor *US6902884 (2005)*.
12. Tso, J.Y., Green, J.M. Anti-HLA-DA antibodies and the methods of using thereof *US6894149 (2005)*.
13. Reiter, R.E., Witte, O.N., Raitano, A.B. PSCA: prostate stem cell antigen and uses thereof. *US6881822 (2005)*.
14. Andersen, R., Coleman, J., De Silva, D., Kong, F., Piers, E., Wallace, D., Roberge, M., Allen, T. Biologically active peptides and compositions, their use *US6870028 (2005)*.
15. Calabresi, P., Darnowski, J. Combination drug therapy *US6849599 (2005)*.
2. McGrath, M.S., Herndier, B. Retrovirus isolated from mantle histiocytes in mantle cell lymphoma *US6924095 (2005)* and *US20050186560A1 (2005)*.
3. Kano, R., Hasegawa, A., Inoue, C. Canine CD20 gene *WO05075640A1 (2005)*.
4. Chatterjee, M., Foon, K.A., Chatterjee, S.K. Murine monoclonal anti-idiotypic antibody 11D10 and methods of use thereof *US6949244 (2005)*.
5. Munoz Saez, M. Use of non-peptidic NK1 receptor antagonists for the production of apoptosis in tumour cells *WO05077366B1 (2005)*.
6. Moritz, A., Lee, K., Rush, J., Polakiewicz, R. Protein phosphorylation in anaplastic large cell lymphoma *WO05083439A1 (2005)*.
7. Muñoz Sáez, M. Use of non-peptidic NK1 receptor antagonists for the production of apoptosis in tumour cells *WO05077366A1 (2005)*.
8. Ranki, A., Karenko, L., Kahkonen, M., Karhu, R., Visakorpi, T., Nedoszytko, B. Method for the diagnosis of lymphoproliferative diseases *US20050221309A1 (2005)*.
9. Tsai, D. Methods for use of TARGRETIN in organ transplant rejection, autoimmune diseases and cancer *US20050209335A1 (2005)*.
10. Anderson, D.R., Hanna, N., Leonard, J.E., Newman, R.A., Reff, M.E., Rastetter, W.H. Therapeutic application of chimeric and radiolabeled antibodies to human B Lymphocyte restricted differentiation antigen for treatment of B cell Lymphoma *US20050186205A1 (2005)*.
11. Hanna, N. Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma *US20050180975A1 (2005)*.
12. Levite, M., Koch, Y. Methods and pharmaceutical compositions for gnrh-II and gnrh-II modulation of t-cell activity, adhesion, migration and extravasation *US20050158309A1 (2005)*.
13. Uckun, F.M., Benyumov, A.O. Transgenic zebra fish embryo model for hematopoiesis and lymphoproliferative disorders *US6953875 (2005)*.
14. Yu, G.-L., Ni, J., Dixit, V., Gentz, R.L., Dillon, P.J. Death domain containing receptors *US6951735 (2005)*.
15. Meyer-Almes, F.-J. Chemosensitivity determination using phosphatidylserine *US6949350 (2005)*.
16. Rameshwar, P. Hematopoietic growth factor inducible neurokinin-1 gene *US6939955 (2005)*.
17. Koprski, M.S. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer *US6939671 (2005)*.
18. Pressman, N.J., Hirsch, A., Hirsch, K.S. Cell-based detection and differentiation of lung cancer *US6939670 (2005)*.
19. Fogelman, A.M., Navab, M. G-type peptides to ameliorate atherosclerosis *US6930085 (2005)*.

LYMPHOMA AND LEUKEMIA

1. Siegall, C.B., Wahl, A.F., Francisco, J.A., Fell, H.P. Jr. Recombinant anti-CD40 antibody and uses thereof *US6946129 (2005)*.

20. Anderson, D.R., Hanna, N., Brams, P. Treatment of Crohn's disease using anti-CD80 antibodies that do not inhibit the binding of CD80 antigen to CTLA-4 **US6926895 (2005)**.
21. Angibaud, P.R., Venet, M.G., Bourdrez, X.M. 1, 2-annulated quinoline derivatives **US6914066 (2005)**.
22. Ensor, C.M., Clark, M.A., Holtsberg, F.W. PEG-modified uricase **US6913915 (2005)**.
23. Zhang, W.-W., Roth, J.A. Recombinant p53 adenovirus methods and compositions **US6905873 (2005)**.
24. Raz, E., Lois, A., Takabayashi, K. Agents that modulate DNA-PK activity and methods of use thereof **US6893821 (2005)**.
25. de Boer, M., Conroy, L.B. Method for treating an IgE-mediated disease in a patient using anti-CD40 monoclonal antibodies **US6899879 (2005)**.
26. Russell, S.J., Peng, K.-W. Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family **US6896881(2005)**.
27. Donovan, K.A., Lust, J.A. IL1- : A new target for myeloma therapy **US6864047 (2005)**.
28. Uckun, F.M., Zheng, Y., Ghosh, S. Inhibitors of the EGF-receptor tyrosine kinase and methods for their use **US6864286 (2005)**.
29. McKearn, J.P., Gordon, G., Cunningham, J.J., Gately, S.T., Koki, A.T., Masferrer, J.L. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia **US6858598 (2005)**.
30. White, C. Treatment of B-cell associated diseases **US6846476 (2005)**.
31. Rosenblum, M.G., Mehta, K. Potentiation of anti-CD38-immunotoxin cytotoxicity **NZ0512840A (2005)**.
32. Lu, D. Arsenious sulphide compounds other than As₂O₃ for treating hematological cancers such as leukemia or lymphoma **NZ0526746A (2005)**.
33. Dai, K.-S. Use of human RPS6KA6-related gene variant for diagnosing T cell lymphoblastic lymphoma **EPI580282A1 (2005)**.
34. Lu, D. Arsenic sulfide compounds and derivates thereof for the treatment of malignancies **EPI552841A1 (2005)**.
35. Bensussan, A., Bagot, M., Boumsell, L., Moretta, A. Novel means for the diagnosis and therapy of CTCL **US20050074761A1 (2005)**.
36. Witzig, T.E., Kaufmann, S.H. Method of treating mantle cell lymphoma **US20050113403A1 (2005)**.
37. Managoli, N. Herbo-mineral formulation for refractory leukemias and lymphomas **US20050058722A1 (2005)**.
38. Shipp, M., Aguiar, R., Yakushijin, Y. Lymphoma associated molecules and uses therefore **US20050014186A1 (2005)**.
39. Anand, N.K., Blazey, C.M., Bowles, O.J., Bussenius, J., Costanzo, S., Curtis, J.K., Dubenko, L., Kennedy, A.R., Khoury, R.G., Kim, A.I., Manalo, J.-C.L., Peto, C.J., Rice, K.D., Tsang, T.H. Anaplastic lymphoma kinase modulators and methods of use **WO05009389A3 and WO05009389A2 (2005)**.
40. Witzig, T.E., Kaufmann, S.H. CCI-779 For treating mantle cell lymphoma **WO05046681A1 (2005)**.
41. Green, S., Giannella-Borradori, A., Bertoni, F. Roscovitine treatment of mantle cell lymphoma **WO05044274A1 (2005)**.
42. Bacopoulos, N.G., Chiao, J.H., Miller, T.A., Paradise, C.M., Richon, V.M. Method of treating cancer with HDAC inhibitors **WO05018578A3 and WO05018578A2 (2005)**.
43. Seto, M., Tagawa, H., Yoshida, Y., Kira, S. Disease type of lymphoma and method of assessing prognosis **WO05028648A1 (2005)**.
44. Ni, J., Gentz, R.L., Yu, G.-L., Rosen, C.A. Death domain containing receptor 5 antibodies **US6872568 (2005)**.
45. Robinson, R.R., Liu, A.Y., Ledbetter, J.A. Chimeric antibody with specificity to human B cell surface antigen **US6893625 (2005)**.
46. Tso, J.Y., Green, J.M. Anti-HLA-DA antibodies and the methods of using thereof **US6894149 (2005)**.
47. Saltman, D. Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase II inhibitor and the use thereof for treating neoplasia **WO05011698A1 (2005)**.
48. McArthur, J.G., Liang, L. Methods and compositions for the treatment of cell lymphomas and other cancers **WO05046613A2 (2005)**.
49. Warrell, R.P. Jr., Pandolfi, P.P., Gabrilove, J.L. Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol **US6861076 and US6855339 (2005)**.
50. Spaner, D.E., Miller, R.L. Treatment for CD5⁺ B cell lymphoma **WO05023190A2 (2005)**.
51. Miller, R.L., Spaner, D.E. Treatment for CD5⁺ B cell lymphoma **US20050054665A1 (2005)**.
52. LPez Blanco, J.M., Camp, S.M., Gil S. Novel therapeutic use of riboside of 5-aminoimidazole-4-carboxamide (acadesine) **EPI508333A1 (2005)**.
53. Anderson, D.R., Brams, P., Hanna, N., Shestowsky, W.S., Heard, C. Methods for treating b cell lymphoma using CD80-specific antibodies **US6893638 (2005)**.
54. Leung, S-O., Hansen, H. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells **US20050106108A1 (2005)**.
55. Ellison, R.M., Mermelstein, F.H. Compositions and methods for non-targeted activation of endogenous genes **US6897066 (2005)**.
56. Rybak, M.E., Rose, E.H. Melanoma therapy **US6923966 (2005)**.

57. Garcia Boy, R., Lyko, F., Siedlecki, P. Inhibitors of DNA methylation in tumor cells **WO05085196A2 (2005)**.
58. Clark-Lewis, I., Gong, J.-H., Duronio, V. Therapeutic chemokine receptor antagonists **US6946445 (2005)**.
59. Garcia Boy, R., Lyko, F., Siedlecki, P. Inhibitors of DNA methylation in tumor cells **EP1574499A1 (2005)**.
60. Bebbington, C.R., Nieder, M.H., Cardarelli, P.M., Gangwar, S., Pickford, L.B., Pan, C. CD10-Activated prodrug compounds **US6897034 (2005)**.
61. Imoto, I., Yuki, Y., Imaizumi, Y. Novel chimeric protein, gene encoding the same, and means of judging leukemia using the gene and the protein **WO05082933A1 (2005)**.
62. Nardella, F.A. Methods and compositions for the treatment of chronic lymphocytic leukemia **US6921772 (2005)**.
63. Falchuk, K.H. Compounds and methods for regulating cell differentiation **US6908732 (2005)**.
64. Hanna, N. Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma **US6896885 (2005)**.
65. Olopade, O.I. Methylthioadenosine phosphorylase compositions and methods of use in the diagnosis and treatment of proliferative disorders **US6870037 (2005)**.
66. Andersson, B.S. Topical formulations of natamycin/pimaricin **US6844004 (2005)**.
67. Won, J., Hue, Y.-G., Kim, S.-J., Park, S.-H., Park, D. Pharmaceutical composition comprising hydroxyphenyl derivatives of rosmarinic acid for anticancer **WO05072723A1 (2005)**.
68. Lyons, J. Method for treating chronic myelogenous leukemia **US20050209186A1 (2005)**.
69. Liao, M.-C. Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof **US20050181065A1 (2005)**.
70. Banerjee, A.K., Giri, V.S., Mukherjee, R., Kapoor, K.K., Desiraju, Ga., Jaggi, M., Singh, A.T., Dutta, S.K., Sairam, K.V.V.M. Hydroanthracene based compounds as anticancer agents **US6949557 (2005)**.
71. Pisano, C., Riccioni, T. Compositions useful for the treatment of pathologies responding to the activation of PPAR- receptor **US6897235 (2005)**.
72. Kikuchi, K., Hibi, S. Heterocycle-containing carboxylic acid derivative and drug containing the same **US6884808 (2005)**.

CHK1 INHIBITORS

1. Ferrick, D.A., Swift, S.E., Armstrong, R., Fox, B. Vector for screening for modulators of IgE synthesis, secretion and switch rearrangement **US6953688 (2005)**.
2. Kawabe, T., Kobayashi, H. Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or

augment the anti-cancer activity of DNA-damaging treatments **EP1511713A2 (2005)**.

3. Clark, D., Keegan, K.S., Peterson, S., Weidner, M. Use of CHK1 inhibitors to control cell prolifer **WO05027907A1 (2005)**.

DIARYLUREA DERIVATIVES

1. Dahl, B.H., Christophersen, P., Engsig, M.T., Karsdal, M.A., Foged, N.T., Jensen, F.R. Diarylurea derivatives and their use as chloride channel blockers **EP1537075A2 (2005)**.

AMINOPYRAZOLES

1. Benbow, J.W., Kung, D.W.-S. Aminopyrazole derivatives as GSK-3 inhibitors **WO05051919A1 (2005)**.
2. Johnson, M.D., Teng, M., Zhu, J. Aminopyrazole compounds and use as CHK1 inhibitors **WO05009435A1 (2005)**.
3. Johnson, M.D., Teng, M., Zhu, J. Aminopyrazole compounds **US20050043381A1 (2005)**.
4. Minami, N., Sato, M., Hasumi, K., Yamamoto, N., Keino, K., Matsui, T., Kanada, A., Ohta, S., Saito, T., Sato, S., Asagarasu, A., Doi, S., Kobayashi, M., Sato, J., Asano, H. Aminopyrazol derivate **DE69926542C0 (2005)**.
5. Ho, C.Y., Galemno, R.A. Jr., Johnson, D.L., Mei, J.M., Belkowski, S.M., Connors, R.W. Immobilized N-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets **US20050130910A1 (2005)**.
6. Ho, C.Y., Galemno, R.A. Jr., Johnson, D.L., Mei, J.M., Belkowski, S.M., Connors, R.W. Immobilized n-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets **WO05049579A3** and **WO05049579A3 (2005)**.
7. Minami, N., Sato, M., Hasumi, K., Yamamoto, N., Keino, K., Matsui, T., Kanada, A., Ohta, S., Saito, T., Sato, S., Asagarasu, A., Doi, S., Kobayashi, M., Sato, J., Asano, H. Aminopyrazole derivatives **EP1142890B1 (2005)**.
8. Ho, C.Y., Brunmark, B.A., Emanuel, S., Galemno R.A. Jr., Johnson, D.L., Ludovici, D.W., Maharroof, U., Mei, J.M., Sechler, J.L., Strobel, E.D., Tuman, R.W., Yen, H.K. N-Substituted tricyclic 3-aminopyrazoles as PDGF receptor inhibitors **EP1506175A1 (2005)**.

ANTI-CANCER AGENTS

1. Lee, B.-R. Anticancer therapy-aiding composition comprising polyphenol, and ascorbic acid or the derivatives **WO05063235A1 (2005)**.
2. Tanaka, A., Yamazaki, A., Tsutsumi, T., Terada, T., Haramura, M. Novel target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto **WO05054181A1 (2005)**.
3. McMorris, T.C., Kelner, M.J. Antitumor agents **US6908918 (2005)**.

4. Kasprzyk P.G., Prevost G. Principe-Nicolas P., Anti-cancer agent and method for treating cancer **JP2005008534A2 (2005)**.
5. Kotani, H., Kaneda, Y., Kawano, H., Fukumura, M., Kurooka, M. Composition having antitumor effect **WO05094878A1 (2005)**.
6. Ono, N. Anticancer agent **WO05085215A1 (2005)**.
7. Tanaka, A., Tamura, T., Haramura, M. Novel anti-cancer agent "sulcoxin **WO05054216A1 (2005)**.
8. Dashnamoorthy, R., Das, K.C. Thioredoxin increases redox-cycling of anticancer agents thereby sensitizes cancer cells to apoptosis **US20050208037A1 (2005)**.
9. Fakih, M., Rustum, Y.M., Pendyala, L., Smith, P. Method of augmenting the antitumor activity of anticancer agents **US20050197399A1 (2005)**.
10. Wang, Z.-P. Saponins as anticancer agent **US20050175623A1 (2005)**.
11. Motoyama, J. Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same **US20050119193A1 (2005)**.
12. Banerjee A.K., Giri, V.S., Mukherjee, R., Kapoor, K.K., Desiraju, G., Jaggi, M., Singh, A.T., Dutta, S.K., Sairam, K.V.V.M. Hydroanthracene based compounds as anticancer agents **US6949557 (2005)**.
13. Koya, K., Sun, L., Chen, S., Tatsuta, N., Wu, Y., Ono, M. Taxol enhancer compounds **US6924312 (2005)**.
14. Hasumi, K., Shimizu, K., Yamamoto, T. Anticancer agent containing BL angiostatin **WO05079835A1 (2005)**.
15. Dai, D., Musser, J.H., Yuan, H. Triplide 5, 6-derivatives as immunomodulators and anticancer agents **WO05062913A3** and **WO05062913A3 (2005)**.
16. Young, A.H. Biological response modifier for the treatment of cancer **US20050192443A1 (2005)**.
17. Liu, X. Anticancer agents using vero toxin variants **US20050163807A1 (2005)**.
18. Kubota, Y., Uemura, H., Nakaigawa, N., Naito, K. Anticancer agents **US20050119323A1 (2005)**.
19. Chu, C.K., Kotra, L.P., Manouilov, K., Du, J., Schinazi, R. Therapeutic azide compounds **US6949521 (2005)**.
20. Long, C., Olson, E.N., Bristow, M., McKinsey, T.A. Inhibition of histone deacetylase as a treatment for cardiac hypertrophy **US6946441 (2005)**.
21. Holton, R.A., Fang, W. Taxanes having a C10 carbamoyloxy substituent **US6906088 (2005)**.
22. Cook, P.D. Nucleobase heterocyclic combinatorialization **US6893815 (2005)**.
23. Srivastava, S.K., Khan, M., Khanuja, S.P.S. Process for isolation of anticancer agent camptothecin from *Nothapodytes foetida* **US6893668 (2005)**.
24. Yamamoto, S., Kotani, H., Kaneda, Y. Medicinal preparation having chemotherapeutic encapsulated therein **EP1568379A1 (2005)**.
25. Liu, X., Anticancer agents using vero toxin variants **EP1496116A4 (2005)**.
26. Hippo, Y., Watanabe, A., Fukayama, M., Ito, Y., Arai, M., Ito, H., Ohtomo, T., Funahashi, S.-I., Kinoshita, Y. Cancer diagnosis and treatment using anti-ROBO1 antibody **WO05095981A1(2005)**.
27. Kimura, M., Iwagaki, H., Tsunenaga, M., Inoue, S. Agent for generating heat or singlet oxygen and composition for cancer treatment each comprising organic peroxide or chemiluminescent compound **WO05095356A1 (2005)**.
28. Massiot, G., Long, C., Ausseil, F., Knibiehler, M., Canitrot, Y., Hoffmann, J.-S., Cazaux, C., Benaim, P. Use of a masticadienonic acid in the form of a dna polymerase beta inhibitor **WO05094837A1 (2005)**.
29. Reddy, E.P., Reddy, M.V.R., Bell, S.C. Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders **WO05089269A2 (2005)**.
30. Oyaizu, K., Yamaguchi, A., Hanyuu, Y., Kasahara, K., Komuro, M. Niosome having metal porphyrin complex embedded therein, process for producing the same and drug with the use thereof **WO05084665A1 (2005)**.
31. Yuan, H., Musser, J.H., Dai, D. Triptolide lactone ring derivatives as immunomodulators and anticancer agents **WO05084365A2 (2005)**.
32. Minami, T., Kodama, T., Hamakubo, T., Iwanari, H., Hayashi, M. Drug for treating and preventing cancer **WO05082412A1 (2005)**.
33. Saito, S. Processes for production of -aminoxyketones and -hydroxyketones **WO05080318A1 (2005)**.
34. Tidmarsh, G. Anti-cancer therapies **WO05076888A2 (2005)**.
35. Hattori, K., Niizuma, S., Eda, H., Tatsuno, K., Yoshida, M. 1-(2H)-Isoquinolone derivatives and use thereof as anticancer agents **WO05075432A1 (2005)**.
36. Wang, W., Ni, Z.-J., Barsanti, P., Pecchi, S., Xia, Y., Brammeier, N., Treutle, M., Jazan, E., Wayman, K., Dibble, D., Cheng, J.-K. Tetrahydrocarboline compounds as anticancer agents **WO05070930A2 (2005)**.
37. Choi, I., Kang, H.-S., Yoon, S.-R., Kim, E.-M. Differentiation regulating agent containing gene which regulating differentiation from stem cells into natural killer cells as effective ingredient **WO05068633A1 (2005)**.
38. Kwon, B.-M., Son, K.-H., Han, D.C., Kho, Y.-H., Chun, H.-K., Kim, H.M., Lee, C.-W. Pharmaceutical composition for treating and preventing cancer comprising *Cinnamoni cortex* extract and *Zizyphi fructus* extract **WO05063255A1 (2005)**.
39. Berdini, V., Saxty, G., Verdonk, M.L., Woodhead, S.J., Wyatt, P.G., Boyle, R.G., Sore, H.F., Walker, D.W.,

- Collins, I., Downham, R., Carr, R.A.E. Pyrazole derivatives as protein kinase modulators **WO05061463A1 (2005)**.
40. Nair, M.G., Zhang, Y., Vareed, S.K. Method for inhibiting cancer cells **WO05054428A2 (2005)**.
41. Wang, W., Lagniton, L.M., Constantine, R.N., Desai, M.C. Quinazolinone compounds as anticancer agents **WO05051922A1 (2005)**.
42. Reddy, P.E., Reddy, R.M.V., Bell, S.C. Alpha, beta-unsaturated sulfoxides for treating proliferative disorders **WO05046599A3** and **WO05046599A2 (2005)**.
43. Xu, Z.-Q., Zhou, Y., Flavin, M.T. Indolocarbazole anticancer agents and methods of using same **WO05039484A3** and **WO05039484A2 (2005)**.
44. Cha, M.Y., Bang, K.C., Ahn, Y.G., Kim, M.S., Lee, G.S. Novel P-glycoprotein inhibitor, method for the preparation thereof and pharmaceutical composition comprising the same **WO05033101A1 (2005)**.
45. Debatin, K.M., Fulda, S. Smac-peptides as therapeutics against cancer and autoimmune diseases **US20050222387A1 (2005)**.
46. Ferrante, A., Easton, J.C., Hii, S.T.C. Anti-cancer nitro- and thia-fatty acids **US20050222253A1 (2005)**.
47. Wang, W., Ni, Z.-J., Barsanti, P., Pecchi, S., Xia, Y., Brammeier, N., Phillips, M.C., Jazan, E., Wayman, K., Dibble, D., Cheng, J.-K. Tetrahydrocarboline compounds as anticancer agents **US20050215580A1 (2005)**.
48. Wang, W., Lagniton, L., Constantine, R.N., Desai, M.C. Quinazolinone compounds as anticancer agents **US20050209254A1 (2005)**.
49. Tocque, B. Combined therapeutical treatment of hyperproliferative diseases **US20050209177A9 (2005)**.
50. Schaffner, C.P., Solomon, K.R. Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors **US20050209167A1 (2005)**.
51. Sircar, J.C., Richards, M.L. Use of benzimidazole analogs in the treatment of cell proliferation **US20050197375A1 (2005)**.
52. Sugiyama, H., Bando, T., Saito, I. Novel hairpin polyamide **US20050176647A1 (2005)**.
53. Akao, A., Kawasaki, M., Kamatani, A., Mase, T., Process for producing indolopyrrolocarbazole derivative **US20050176968A1 (2005)**.
54. Srivastava, S.C., Bajpai, S.K., Sit, K.-H. Novel oligonucleotides and related compounds **US20050159375A1 (2005)**.
55. Arakawa, H., Monden, Y., Nakatsuru, Y., Kodera, T. Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination **US20050171036A1 (2005)**.
56. Wang, J., Qu, H., Wang, L., Wang, T. Supermolecular carboplatinum derivatives, their preparation and pharmaceutical composition containing tem as active ingredient and applications of the compositions **US20050165093A1 (2005)**.
57. Prestwich, G.D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents **US20050169883A1 (2005)**.
58. Secrist J.A.III, Tiwari, K.N., Montgomery J.A. 4'-Thio-L-xyloy furanosyl nucleosides, precursors thereof, preparation and use thereof **US20050130969A1 (2005)**.
59. Dimoudis, N., Kopetzki, E., Lanzendoerfer, M., Scheuer, W. Conjugates of the c domain of human gelatinase a and polyethylene glycol, methods of purification and uses thereof **US20050153416A1 (2005)**.
60. Reddy, E.P., Reddy, M.V.R., Bell, S.C. Amino-substituted (e)-2, 6-dialkoxystryryl 4-substituted-benzylsulfones for treating proliferative disorders **US20050130942A1 (2005)**.
61. Choi, C.W., Park, M.H., Hwang, S.H., Woo, S.G., Song, M.K., Im, J.J., Hong, S.G., Kim, J.H., Jang, J.S., Kim, H.Y. Novel microorganism *Pediococcus pentosaceus* EROM101, having immune enhancement, anticancer and antimicrobial activities **US20050130288A1** and **EP1544288A1 (2005)**.
62. von Borstel, R.W. Compositions and methods for treatment of mitochondrial diseases **US6956028 (2005)**.
63. Poulin, R., Audette, M., Charest-Gaudrealt, R. Polyamine transport inhibitors **US6949679 (2005)**.
64. Trova, M.P. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents **US6949559 (2005)**.
65. Aquila, B.M., Cuny, G.D., Hauske, J.R., Shao, L., Wu, X. 3-Substituted piperidines comprising urea functionality, and methods of use thereof **US6946477 (2005)**.
66. Dai, D., Musser, J.H. Halogenated triptolide derivatives as immunomodulators and anticancer agents **US6943259 (2005)**.
67. Douglas, M.G., Amin, A.N. Pharmaceutical agents containing acyclovir, fusaric acid and derivatives thereof **US6939884 (2005)**.
68. Stevens, M.F.G., Wells, G., Westwell, A.D., Poole, T.D. 4-Aryl quinols and analogs thereof as therapeutic agents **NZ0530787A (2005)**.
69. Frydman, B., Marton, L.J., Valasinas, A.L., Reddy, V.K. Novel polyamine analog-amino acid conjugates useful as anticancer agents **EP1337504A4 (2005)**.
70. Isobe, Y., Ogita, H., Tobe, M., Takaku, H., Ogino, T., Kurimoto, A., Kawakami, H. Novel adenine derivatives **EP1386923A4 (2005)**.
71. Dai, D., Musser, J.H. Triptolide derivatives as immunomodulator and anticancer agents **EP1581208A1 (2005)**.
72. Gant, T.G., Noe, M.C., Larson, E.R. Isothiazole derivatives useful as anticancer agents **CA2333703C (2005)**.

73. La Greca, S.D., Yang, B.V., Lyssikatos, J.P. Quinolin-2-one derivatives useful as anticancer agents **CA2341739C (2005)**.
74. Yang, B.V. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents **EP1150973B1 (2005)**.
75. Matsuhisa, A., Kinoyama, I., Toyoshima, A., Nakahara, T., Takeuchi, M., Okada, M. Fused imidazolium derivatives **EP1256576B1 (2005)**.
76. Reddy, E.P., Reddy, M.V.R. (E)- Styryl sulfone anticancer agents **EP1173160B1 (2005)**.
77. Kadow, J.F., Schwartz, W.S., Scola, P.M., Xue, Q.M., Wittman, M.D., Wu, M.-J. Taxane anticancer agents **EP1263749B1 (2005)**.
78. Noble, M., Dietrich, J. Caspase inhibitors as anticancer agents **EP1545509A2 (2005)**.
79. Shirakiya, Y., Kawashima, T., Kyo, S., Fujiwara, T., Tanaka, N. Tumor-lysing virus growing selectively in tumor cells **EP1553178A1 (2005)**.
80. Cavazza, C., Pisano, C., Vesci, L. Acetyl-L-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents **EP1562577A1 (2005)**.
81. Kamal, A., Reddy, P.S.M.M. 4-Beta-1"-[(2"-(substituted benzoyl)anilino)] podophyllotoxin analogues useful as anticancer agents **EP1377588B1 (2005)**.
82. Secrist, J.A. III., Tiwari, K.N., Montgomery, J.A. 4'-Thio-L-xylofuranosyl nucleosides, precursors thereof, preparation and use thereof **US6914061 (2005)**.
83. Barth, F., Millan, J., Oustric, D., Rinaldi, M., Vernhet, M. 1-Benzylpyrazole-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists **US6916838 (2005)**.
84. Campbell, M., Ibrahim, P.N., Zablocki, J.A., Lawn, R. ABCA-1 elevating compounds **US6919339 (2005)**.
85. Chen, H. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof **US6919370 (2005)**.
86. Sorenson, R.J. Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors **US6924276 (2005)**.
87. Schaffner, C.P., Solomon, K.R., Freeman, M.R. Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors **US6933292 (2005)**.
88. Yamamoto, T., Matsueda, H., Naito, M., Arai, I., Yatagai, M. Process for preparing aminostilbene derivatives **US6930205 (2005)**.
89. Yang, L.-X. Nitrogen-based homo-camptothecin derivatives **US6933302 (2005)**.
90. Bissery, M.-C. Combination comprising combretastatin and anticancer agents **US6933320 (2005)**.
91. Brown, M.S., Goldstein, J.L., Reiss, Y. Methods and compositions for inhibiting farnesyl transferase enzyme **US6936431 (2005)**.
92. Greenwald, R.B., Choe, Y.H. Prodrugs of anticancer agents employing substituted aromatic acids **US6936597 (2005)**.

ANGIOGENESIS

1. Hembrough, T., Pribluda, V.P., Papathanassiou, A.E., Green, S.J. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments **US6946439 (2005)**.
2. O'Reilly, M.S., Folkman, M.J., Cao, Y. Methods of inhibiting angiogenesis via increasing *in vivo* concentrations of kringle region fragments of plasminogen **US6949511 (2005)**.
3. Agrez, M.V., Ahmed, N. Map kinase integrin-binding domain **US20050214755A1 (2005)**.
4. Tosato, G., Pike, S.E., Yao, L. Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth **US20050208018A1 (2005)**.
5. Wang, H.U., Chen, Z., Anderson, D.J. Artery- and vein-specific proteins and uses therefore **US20050204412A1 (2005)**.
6. Chang, J.-K. Angiogenesis regulation system **US20050203015A1 (2005)**.
7. Clark-Lewis, I., Gong, J.-H., Duronio, V. Therapeutic chemokine receptor antagonists **US6946445 (2005)**.
8. Jakubowski, A., Burkly, L. Method for promoting neovascularization **US6943146 (2005)**.
9. Teicher, B., Roberts, B., Kataoka, S., Tahara, T., Honma, N. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis **WO05086713A2 (2005)**.
10. Mazar, A.P., Pirie-Shepherd, S., Betancourt, O. Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents **WO05083107A2 (2005)**.
11. Lorens, J., Holland, S.J., Xu, W. Modulators of angiogenesis and tumorigenesis **WO05080984A1 (2005)**.
12. Li, L.-Y., Zhai, Y., Yu, G.-L., Ni, J., Lippman, M.E., Rosen, C.A. VEGF, an inhibitor of angiogenesis and tumor growth **US20050214305A1 (2005)**.
13. Deng, D.X.- F., Tsalenko, A., Bruhn, L., Yakhini, Z., Ho, M., Quertermous, T., Yang, E. Endothelial cell markers and related reagents and methods of use thereof **US20050207974A1 (2005)**.
14. Penner, R., Fleig, A. Methods of screening for LTRPC2 modulators **US20050202472A1 (2005)**.
15. May, J.A., Feng, Z., Dantanarayana, A.P. 6-hydroxy-indazole derivatives for treating glaucoma **US6956036 (2005)**.

16. Bird, T.G.C. Benzoxazinone derivatives for use in the treatment of angiogenesis *US6951855 (2005)*.
17. Strobel, H., Wohlfart, P. Acylated 1, 2, 3, 4 - tetrahydronaphthyl amines and their use as pharmaceutical agents *US6949556 (2005)*.
18. Chernajovsky, Y., Dreja, H., Adams, G. Latent fusion protein *US6942853 (2005)*.
19. Rosen, C.A., Haseltine, W.A. Albumin fusion proteins *US6946134 (2005)*.
20. Papathanasiou, A. Use of efrapeptin oligopeptides for inhibition of angiogenesis *EP1384484B1 (2005)*.
21. Gribkoff, V.K., Post - Munson, D.J., Yeola, S.W., Boissard, C.G., Hewawasam, P. Selective MAXI-K-potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof *EP1330426A4 (2005)*.
22. Plou, T.J.P., Pedron, S.F., Maitre-Boube, M.M. Novel endothelial cells, antibodies directed against said cells and use thereof, in particular for screening angiogenesis inhibiting substances *EP1549741A1 (2005)*.
23. Kelly, M.G., Xu, S., Xi, N., Miller, P., Kincaid, J.F., Ghiron, C., Coulter, T. Calcium receptor modulating agents *US6908935 (2005)*.
24. D'Amato, R.J., Folkman, M.J. Estrogenic compounds as anti-mitotic agents *US6908910 (2005)*.
25. Green, L.R., Blasecki, J.W. Pharmaceutical angiostatic dipeptide compositions and methods of use thereof *US6911431 (2005)*.
26. Liu, S. Macrocyclic chelants for metallopharmaceuticals *US6916460 (2005)*.
27. Sims, P.J., Bothwell, A.L.M., Elliot, E.A., Flavell, R.A., Madri, J., Rollins, S., Bell, L., Squinto, S. Universal donor cells *US6916654 (2005)*.
28. Shinagawa, Y., Katsushima, T., Nakagawa, T. Calcium receptor antagonist *US6916956 (2005)*.
29. Bouck, N.P., Dawson, D.W., Gillis, P.R., Volpert, O., Crawford, S.E., Stellmach, V.M. Methods and compositions for inhibiting angiogenesis *US6919309 (2005)*.
30. Khan, N.A., Savelkoul, H.F.J., Benner, R. Immunoregulator *US6921751 (2005)*.
31. Garen, A., Hu, Z. Neovascular-targeted immunocjugates *US6924359 (2005)*.
32. Rosen, C.A., Haseltine, W.A. Albumin fusion proteins *US6926898 (2005)*.
33. Kinch, M.S., Zantek, N.D., Hein, P.W. Treatment of metastatic disease *US6927203 (2005)*.
34. Nawroth, P., Nakagawa, K., Zhang, Y. Tissue factor for influencing blood vessel formation *US6930094 (2005)*.
35. D'Amato, R.J., Folkman, M.J. Estrogenic compounds as anti-mitotic agents *US6930128 (2005)*.
36. Bachmann, M.F., Maurer, P. Hapten-carrier conjugates and uses thereof *US6932971 (2005)*.
37. Bayne, M.L., Conn, G.L., Thomas, K.A., Jr. DNA molecules encoding vascular endothelial cell growth factor II subunits *US6933134 (2005)*.
38. Lorens, J.B., Atchison, R.E., Frieria, A., Holland, S. Modulators of angiogenesis and tumorigenesis *US20050118604A1 (2005)*.
39. Ullrich, A., Risau, W., Millauer, B., Gazit, A., Levitzki, A. FLK-1 is a receptor for vascular endothelial growth factor *US20050107321A1 (2005)*.
40. Harris, T.D., Yalamanchili, P. Compounds containing matrix metalloproteinase substrates and methods of their use *US20050106100A1 (2005)*.
41. Kim, S. Method for stimulating wound healing *US20050119175A1 (2005)*.
42. Jayaraman, T. Inositol 1, 4, 5-triphosphate receptor (type 1), phosphorylation and modulation by CDC2 *US20050119179A1 (2005)*.
43. McCrae, K., Donate, F., Juarez, J., Mazar, A.P. Cell surface tropomyosin as a target of angiogenesis inhibition *US20050124794A1 (2005)*.
44. Sullivan, D.C., Bicknell, R. Therapeutic and diagnostic applications of protein disulphide isomerases *US20050153361A1 (2005)*.
45. Krishnan, R. Method of inhibiting angiogenesis *US20050143463A1 (2005)*.
46. Akella, R., Ranieri, J. Compositions and methods for promoting myocardial and peripheral angiogenesis *US20050143312A1 (2005)*.
47. St.Croix, B., Vogelstein, B., Kinzler, K.W. Endothelial cell expression patterns *US20050142138A1 (2005)*.
48. Harats, D., Greenberger, S. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis *US20050186179A1 (2005)*.
49. Harding, J.W., Wright, J.W. AT4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents *US20050222044A1 (2005)*.
50. Azenabor, A.A. Treatment of chronic bacterial infection *WO05007082C1 (2005)*.
51. Zhong, P., Luo, P., Wang, K.C., Hsieh, M., Li, Y. Humanized antibodies against vascular endothelial growth factor *WO05054273A2 (2005)*.
52. Munin Corporation CCN1 compositions and methods *WO05040191A2 (2005)*.
53. Tang, P.C., Sun, L., McMahon, G., Hirth, K.P., Shawver, L.K. Indolinone combinatorial libraries and related products and methods for the treatment of disease *US6906093 (2005)*.
54. Potter, B.V.L., Dowden, J., Galione, A. Therapeutics use of pyridinium compounds to modulate NAADP activity *WO05054198A3 and WO05054198A2 (2005)*.
55. Hsu, H., Wooden, S.K., Boyle, W.J. Fhm, a novel member of the TNF ligand supergene family *US6852839 (2005)*.

56. Davis-Smyth, T.L., Chen, H.H., Presta, L., Ferrara, N. Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production *US6897294* (2005).
57. Tang, P.C., Sun, L., McMahon, G. Azaindole tyrosine kinase inhibitors *US6849641* (2005).
58. Prezant, T.R., Heaney, A.P., Melmed, S. Method of regulating biological activity of pituitary tumor transforming gene (PTTG)1 using PTTG2 *US6913926* (2005).
59. Ward, G.E., Conant, C.G., Ward, B., *Toxoplasma gondii* apical membrane antigen-1 *US6902926* (2005).
60. Wang, H.U., Chen, Z., Anderson, D.J. Artery- and vein-specific proteins and uses therefore *US6916625* (2005).
61. Altmann, K.-H., Bold, G., Furet, P., Manley, P.W., Wood, J.M., Ferrari, S., Hofmann, F., Mestan, J., Huth, A., Krüger, M., Seidelmann, D., Menrad, A., Haberey, M., Thierrauch, K.-H. VEGF receptor tyrosine kinase inhibitors *US6878720* (2005).
62. Hirst, G.C., Rafferty, P., Ritter, K., Calderwood, D., Wishart, N., Arnold, L.D., Friedman, M.M. Pyrazolo-pyrimidines as therapeutic agents *US6921763* (2005).
63. Varner, J.A. Methods for inhibiting angiogenesis *US20050129681A1* (2005).
64. Brooks, P., Cheresch, D.A. Inhibition of angiogenesis in disease states with an anti- v 3 monoclonal antibody *US6887473* (2005).
65. Pollitt, N.S., Abraham, J.A. Vascular endothelial growth factor variants *US6887848* (2005).
66. Ronn, L.C., Holm, A., Olsen, M., Ostergaard, S., Jensen, P.H., Poulsen, F.M., Soroka, V., Ralets, I., Berezin, V., Bock, E. NCAM binding compounds *US6887844* (2005).
67. Plouet, J., Jonca, F., Ortega, N., Ruchoux, M.-M. Anti-idiotypic antibodies of vascular endothelial growth factor and use thereof as drugs *US6887469* (2005).
68. Baca, M., Wells, J.A. Anti-VEGF antibodies *US6884879* (2005).
69. Gleave, M., Rennie, P.S., Miyake, H., Nelson, C., Monia, B.P. TRPM-2 antisense therapy using an oligonucleotide having 2'-O-(2-methoxy)ethyl modifications *US6900187* (2005).

EICOSANOIDS AND ANGIOGENESIS

1. Adams, J.L. Substituted imidazole compounds *US6858617* (2005).
2. Demopolos, H.B., Seligman, M.L. Pharmaceutical preparations of glutathione and methods of administration thereof *US6896899* (2005).
3. Sabbadini, R.A. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefore *US6881546* and *US6858383* (2005).

4. Serhan, C.N., Lipoxin compounds and their use in treating cell proliferative disorders *US6887901* (2005).
5. Pandol, S.J., Gukovskaya, A. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof *US6953786* (2005).
6. Liao, J.K., Zeldin, D. Anti-inflammatory actions of cytochrome P450 epoxygenase-derived eicosanoids *US6916843* (2005).
7. Petasis, N.A. Trihydroxy polyunsaturated eicosanoid derivatives *US20050228047A1* (2005).
8. Spiegelman, B.M., Puigserver, P., Wu, Z., Adelmant, G. PGC-1, a novel brown fat PPAR coactivator *US6872391* (2005).
9. Clayton, N.M., Collins, S.D., Foord, S.M., Giblin, G.M.P., Coles, R.J., Bamford, M., Doughty, J.M., Green, R. Use of EP4 receptor ligands in the treatment of neuropathic pain and colon cancer *US6861441* (2005).
10. Adams, J.L., Hall, R.F., Boehm, J.C. Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines *US6861417* (2005).
11. Thompson, R.C., Hannum, C.H., Eisenberg, S.P., Arend, W.P., Joslin, F.G., Sommer, A. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors *US6858409* (2005).
12. Kelly, J., Devane, J., Dinan, T.G., Keeling, P.W.N. Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil *US6849661* (2005).

SIGNAL TRANSDUCTION INHIBITORS

1. Eck, S.L., Fry, D.W., Leopold, J.A.S. Combinations of signal transduction Inhibitors *WO05094830A1* (2005).
2. Eck, S.L., Fry, D.W., Leopold, J.A. Combinations of signal transduction inhibitors *US20050222163A1* (2005).
3. Li, H.-Y., McMillen, W.T., Wang, Y. Fused pyrazole derivatives as TGF-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms *WO05092894A1* (2005).
4. Beight, D.W., Bonjouklian, R., Liao, J., McMillen, W.T., Parkhurst, B.L., Sawyer, J.S., Yingling, J.M., York, J.S. Novel pyrazolopyridine derivatives as pharmaceutical agents *US20050222197A1* (2005).
5. Manoharan, M., Cook, P.D., Prakash, T.P., Mohan, V. Guanidinium functionalized intermediates *US6914148* (2005).
6. Prevost, G., Teillot, M. Product comprising a heterotrimeric G protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension *EP1248651B1* and *US6846822* (2005).
7. Daley, G.Q., Hoover, R.R. Effects of combined administration of farnesyl transferase inhibitors and

signal transduction inhibitors *US20050020516A1 (2005)*.

TUMOR STEM CELL

1. Clarke, M.F., Liu, R. Compositions and methods for treating and diagnosing cancer *WO05005601C1* and *WO05005601A2 (2005)*.
2. Dirks, P., Singh, S.K. Brain tumor stem cells *CA2447400AA (2005)*.

INHIBITORS IN CANCER CHEMOTHERAPY

1. Poulin, R., Audette, M., Charest-Gaudreault, R. Polyamine transport inhibitors *US6949679 (2005)*.
2. Borisy, A., Keith, C., Foley, M.A., Stockwell, B.R. Combinations of drugs for the treatment of neoplastic disorders *US6846816 (2005)*.
3. Brown, D.A., Khorlin, A.A., Lesiak, K., Ren, W.Y. Dermatological compositions and methods *US6955804 (2005)*.
4. Horvitz, H.R., Yuan, J., Shaham, S. Altered human interleukin-1 convertase (ICE), NEDD-2, and *C. elegans* ced-3 polypeptides and uses therefore *US6939850 (2005)*.
5. Roberts, J., Sethuraman, N., MacAllister, T. Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase *US6939541 (2005)*.
6. Greer, S.B. Dramatic simplification of a method to treat neoplastic disease by radiation *US6933287 (2005)*.
7. Fujii, A., Tanaka, H., Otsuki, M., Kawaguchi, T., Oshita, K. Antitumor effect potentiators *US6930115 (2005)*.
8. Hirst, G.C., Rafferty, P., Ritter, K., Calderwood, D., Wishart, N., Arnold, L.D., Friedman, M.M. Pyrazolopyrimidines as therapeutic agents *US6921763 (2005)*.
9. Bodie, N.M., Altman, E. Inhibition of immune complex formation *US6916904 (2005)*.
10. Liu, S. Macrocyclic chelants for metallopharmaceuticals *US6916460 (2005)*.

11. Drewe, J.A., Cai, S.X., Wang, Y. Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof *US6906203 (2005)*.
12. Ullrich, A., Alves, F.H.E. MCK-10 a novel receptor tyrosine kinase *US6897029 (2005)*.
13. Li, C., Wallace, S., Yu, D.-F., Yang, D.J. Water soluble paclitaxel derivatives *US6884817 (2005)*.
14. Webb, T., Chianelli, D., Kim, Y.-C. Somatostatin analogue compounds *US6872827 (2005)*.
15. Taylor, C., Wang, T.-W., Petrov, L., Carlson, J.C., Narayansingh, R., Thompson, J.E. DNA encoding apoptosis-induced eucaryotic initiation factor-5A and deoxyhypusine synthase and a method for controlling apoptosis in animals and humans *US6867237 (2005)*.
16. Hayama, T., Kawanishi, N., Takaki, T. Pyrazinone derivatives *US6914062 (2005)*.
17. Schlessinger, J., Okigaki, M., Gishizky, M. PYK2 and inflammation *US6861442 (2005)*.
18. Cai, S.X., Xu, L., Storer, R., Attardo, G. 7, 8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof *US6858607 (2005)*.
19. Vinson, G.P., Puddefoot, J.R., Berry, M.G. Cancer treatment *US6852316 (2005)*.
20. Calabresi, P., Darnowski, J. Combination drug therapy *US6849599 (2005)*.
21. Copeland, R.A., Albright, C.F., Combs, A.P., Dowling, R.L., Graciani, N.R., Han, W., Higley, C.A., Huang, P.S., Yue, E.W., DiMeo, S.V. Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use *US6844318 (2005)*.
22. Jallal, B., Plowman, G.D. Diagnosis and treatment of PTP04 related disorders *US6844177 (2005)*.
23. Danenberg, K.D. Method of determining dihydropyrimidine dehydrogenase gene expression *US6956111* and *US6905821 (2005)*.